Investor Relations
Corporate Profile
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
- Change
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Jul 01
2024
2024
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Learn More >
Jun 20
2024
2024
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Learn More >
May 23
2024
2024
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Learn More >
May 13
2024
2024
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Learn More >
May 13
2024
2024
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Learn More >
May 06
2024
2024
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Learn More >
Apr 26
2024
2024
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Learn More >
Apr 09
2024
2024
Allogene Therapeutics Announces Q2 Investor Conference Participation
Learn More >
Mar 14
2024
2024
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Learn More >
Mar 12
2024
2024
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Learn More >
Events
May 28, 2024 at 12:30 PM EDT